At this year’s EHA we present our prospective data on a comparison between ATLG and ATG, which means actually the grafalon versus thymoglobulin products. We think this is a very important area of research in hematopoietic stem cell transplantation. We are in a new era where ATLG may offer better outcomes for our patients. Of course, we need more data to prove it and we have to have solid data to prove it...
At this year’s EHA we present our prospective data on a comparison between ATLG and ATG, which means actually the grafalon versus thymoglobulin products. We think this is a very important area of research in hematopoietic stem cell transplantation. We are in a new era where ATLG may offer better outcomes for our patients. Of course, we need more data to prove it and we have to have solid data to prove it. That is why we designed this prospective study and as a second part of this study, which we’ll present it later potentially at ASH, we hope at ASH, and we have also experimental data trying to show differences in endothelial injury markers between patients receiving ATLG or ATG. In this abstract we had the preliminary data of clinical outcomes of these patients and we found a very significant difference in survival between patients receiving ATLG versus ATG. We think this is a continuous development for hematopoietic cell transplantation. We always need to update and to criticize our results and maybe have better outcomes for our patients using ATLG in our conditioning regimens. We had no safety issues with ATLG and the dose we initially used and suggested in this abstract was found to be potentially even better than the traditional ATLG regimen.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
